Specifying a GLP 28-Day Intravenous Repeat-Dose Toxicity and Toxicokinetic Study in Rats: A Request-for-Proposal Framework Built on a Historical Single-Dose Dataset
A single-dose toxicokinetic study answers how much drug reaches the blood, but not what happens when dosing is repeated. This article evaluates the scientific and regulatory rationale for a follow-up GLP 28-day repeat-dose intravenous toxicity study with integrated toxicokinetics and a 14-day recovery phase in Sprague-Dawley rats, using a historical single-dose rat dataset in which systemic exposure rose more than proportionally with dose across 30, 100, and 200 mg/kg. Recalculation of the reported values shows that a 6.7-fold dose range produced roughly 23-fold and 25- to 28-fold increases in peak concentration and exposure, respectively, and that some reported peaks exceeded the stated upper limit of the bioanalytical method. The article converts the rationale into a request for proposal (RFP) that specifies provisional doses, 100 animals, sampling, bioanalytical requirements, a 30-week schedule, and a budget of USD 900,000 to 1,400,000, while stating clearly which values are planning assumptions. It also qualifies the use of an oral guideline for an intravenous design and states that a rat study alone cannot establish a human starting dose.Keywords: request for proposal; repeat-dose toxicity; toxicokinetics; Sprague-Dawley rat; nonlinear exposure; ICH S3A; GLP
Authors
- Mounika Battula
- Peivand Pirouzi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425410
- Primary Topic
- Animal testing and alternatives
- Type
- article
- Field-Weighted Citation Impact
- 0.00